> Details

Sen, Parikshit; R, Naveen; Houshmand, Nazanin; Moghadam Kia, Siamak; Joshi, Mrudula; Saha, Sreoshy; Jagtap, Kshitij; Agarwal, Vishwesh; Nune, Arvind; Nikiphorou, Elena; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Velikova, Tsvetelina; Milchert, Marcin; Parodis, Ioannis; Gracia-Ramos, Abraham Edgar; Cavagna, Lorenzo; Kuwana, Masataka; Knitza, Johannes; Makol, Ashima; Patel, Aarat; Pauling, John D; Wincup, Chris; [...]

Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
  • Contributor: Sen, Parikshit; R, Naveen; Houshmand, Nazanin; Moghadam Kia, Siamak; Joshi, Mrudula; Saha, Sreoshy; Jagtap, Kshitij; Agarwal, Vishwesh; Nune, Arvind; Nikiphorou, Elena; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Velikova, Tsvetelina; Milchert, Marcin; Parodis, Ioannis; Gracia-Ramos, Abraham Edgar; Cavagna, Lorenzo; Kuwana, Masataka; Knitza, Johannes; Makol, Ashima; Patel, Aarat; Pauling, John D; Wincup, Chris; [...]
  • imprint: Oxford University Press (OUP), 2023
  • Published in: Rheumatology
  • Language: English
  • DOI: 10.1093/rheumatology/kead057
  • ISSN: 1462-0324; 1462-0332
  • Keywords: Pharmacology (medical) ; Rheumatology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Objective</jats:title> <jats:p>COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P &amp;lt; 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P &amp;lt; 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P &amp;lt; 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs – OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs – OR: 5.4 95% CI: 3, 9.6, P &amp;lt; 0.001). Caucasians [OR 4.2 (1.7–10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8–0.97)].</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.</jats:p> </jats:sec>